本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
PHILADELPHIA and PERTH, Australia, Feb. 28, 2025 /PRNewswire/ -- Arcadium Lithium plc (NYSE: ALTM, ASX: LTM, "Arcadium Lithium" or the "Company") today reported results for the fourth quarter and full year of 2024. As a result of its pending acquisition by Rio Tinto, announced on October 9, 2024 (the "Transaction"), and as is customary during such transactions, Arcadium Lithium will not hold an earnings conference call in connection with its fourth quarter and full year financial results. For the same reason, the Company withdrew its prior operating and financial guidance and will not be introducing guidance for 2025. For further detail and discussion of Arcadium Lithium's results for the fourth quarter and full year of 2024, please refer to Arcadium Lithium's Annual Report on Form 10-K for the year ended December 31, 2024, being filed today with the Securities and Exchange Commission (the "SEC"). Fourth Quarter and Full Year Highlights Fourth quarter revenue was $289.0 million and reported attributable GAAP net loss was $14.2 million, or 1 cent per diluted share. Adjusted EBITDA1 was $73.7 million and adjusted earnings per diluted share2 was 1 cent. The increase in Adjusted EBITDA1 compared to the third quarter was largely attributable to higher volumes across all lithium products and reduced costs, partially offset by lower average realized pricing. Fourth quarter total volumes sold were 56% higher on an LCE3 basis versus the third quarter, but roughly flat versus the prior year, as customers close out their contractual commitments and demand needs during the typically active year-end in key end markets. The Company realized average pricing of $15,700 per product metric ton for combined lithium hydroxide and carbonate volumes in the fourth quarter, compared to $16,200 in the third quarter. Average realized pricing declined across most lithium products, with the exception of spodumene, due to weaker prevailing market prices. However, lithium hydroxide pricing was roughly flat quarter-over-quarter, supported by customer mix and the benefit of existing long term commercial agreements. Q4 2024 Revenue (M) Volume Unit Price Lithium Hydroxide and Lithium Carbonate4 $211.1 ~13,4505 product metric ton $15,700 / product MT Butyllithium & Other Lithium Specialties $38.9 ~470 LCE3 $82,800 / LCE Spodumene Concentrate $39.0 ~54,100 dry metric ton $721 / 5.4% dmt (~$810 SC6 equivalent) For the full year, Arcadium Lithium reported revenue of $1,007.8 million. Attributable GAAP net income was $103.2 million, or 9 cents per diluted share. Full year Adjusted EBITDA1 was $324.5 million and adjusted earnings per share were 14 cents per diluted share2. Full year total volumes sold were slightly lower on an LCE3 basis, with higher combined lithium carbonate and hydroxide sales more than offset by lower spodumene sales due to reduced production at Mt Cattlin. Average realized pricing over the full year declined across all lithium products in light of a weaker market environment compared to 2023. FY 2024 Revenue (M) Volume Unit Price Lithium Hydroxide and Lithium Carbonate4 $728.9 ~42,3005 product metric ton $17,200 / product MT Butyllithium & Other Lithium Specialties $169.2 ~1,860 LCE3 $91,000 / LCE Spodumene Concentrate $109.7 ~140,000 dry metric ton $784 / 5.4% dmt (~$880 SC6 equivalent) "2024 was highlighted by a focus on executing key initiatives within our control while navigating challenging broader market conditions. This included exercising cost and operational discipline while maintaining the flexibility to adapt to a quickly changing market environment," said Paul Graves, president and chief executive officer of Arcadium Lithium. "Our strong customer relationships and commercial strategy of securing long term contracts helped us to achieve higher realized pricing during the year than we would have under a fully market-based pricing approach. Additionally, at our Investor Day in September we outlined an attractive plan to deliver significant growth over the coming years, leveraging the size and quality of our portfolio of assets and expansion projects. We believe the pending combination with Rio Tinto will give us the ability to accelerate and expand this growth opportunity for the benefit of our customers, our employees, and the communities in which we operate." _______________________ 1 Reconciliation of Adjusted EBITDA, a non-GAAP measure, to net income attributable to Arcadium Lithium plc, the most directly comparable financial measure presented in accordance with GAAP, is set forth in the reconciliation table accompanying this release. 2 Corresponds to Diluted adjusted after-tax earnings per share in the accompanying financial tables. Reconciliation of Diluted adjusted after-tax earnings per share, a non-GAAP measure, to Diluted earnings per ordinary share (GAAP), the most directly comparable financial measure presented in accordance with GAAP, is set forth in the reconciliation table accompanying this release. 3 Lithium Carbonate Equivalents. 4 Includes 100% of Olaroz in which Arcadium Lithium has current economic interest of 66.5%. 5 Excludes lithium carbonate by-product. Rio Tinto Transaction Timeline On October 9, 2024, a definitive agreement (the "Transaction Agreement") was announced under which Rio Tinto will acquire Arcadium Lithium in an all-cash transaction for US$5.85 per share. Requisite Arcadium Lithium shareholder approval for the Transaction was obtained at special meetings held on December 23, 2024. As announced on February 13, 2025, the Company has received all required pre-closing regulatory approvals in connection with the proposed acquisition. This includes merger control clearance being satisfied or waived in Australia, Canada, China, Japan, South Korea, the United Kingdom and the United States (Hart-Scott-Rodino Antitrust Improvements Act of 1976), as well as investment screening approval being satisfied in Australia, Canada, Italy, the United Kingdom and the United States (CFIUS). Arcadium Lithium and Rio Tinto are now targeting closing of the Transaction on March 6, 2025. The Transaction remains subject to Court Order by the Royal Court of Jersey and other customary closing conditions. Arcadium Lithium cannot assure completion of the Transaction by any particular date, if at all, or that if completed, it will be completed on the terms set forth in the Transaction Agreement. Full details of the terms and conditions of the Transaction are set out in the Transaction Agreement, which may be obtained, free of charge, on the SEC's website (http://www.sec.gov). Arcadium Lithium Contacts Investors:Daniel Rosen +1 215 299 6208daniel.rosen@arcadiumlithium.com Phoebe Lee +61 413 557 780phoebe.lee@arcadiumlithium.com Media:Karen Vizental +54 9 114 414 4702karen.vizental@arcadiumlithium.com Supplemental Information In this press release, Arcadium Lithium uses the financial measures Adjusted EBITDA and Diluted adjusted after-tax earnings per share. These terms are not calculated in accordance with generally accepted accounting principles (GAAP). Definitions of these terms, as well as a reconciliation to the most directly comparable financial measure calculated and presented in accordance with GAAP, are provided on our website: ir.arcadiumlithium.com and elsewhere in this press release or the financial tables that accompany this press release. About Arcadium Lithium Arcadium Lithium is a leading global lithium chemicals producer committed to safely and responsibly harnessing the power of lithium to improve people's lives and accelerate the transition to a clean energy future. We collaborate with our customers to drive innovation and power a more sustainable world in which lithium enables exciting possibilities for renewable energy, electric transportation and modern life. Arcadium Lithium is vertically integrated, with industry-leading capabilities across lithium extraction processes, including hard-rock mining, conventional brine extraction and direct lithium extraction (DLE), and in lithium chemicals manufacturing for high performance applications. We have operations around the world, with facilities and projects in Argentina, Australia, Canada, China, Japan, the United Kingdom and the United States. For more information, please visit us at www.ArcadiumLithium.com. Important Information and Legal Disclaimer: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this news release are forward-looking statements. In some cases, we have identified forward-looking statements by such words or phrases as "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words and phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for Arcadium Lithium based on currently available information. There are important factors that could cause Arcadium Lithium's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including the completion of the Transaction on anticipated terms and timing, including obtaining required shareholder and regulatory approvals, and the satisfaction of other conditions to the completion of the Transaction; potential litigation relating to the Transaction that could be instituted by or against Arcadium Lithium or its affiliates, directors or officers, including the effects of any outcomes related thereto; the risk that disruptions from the Transaction will harm Arcadium Lithium's business, including current plans and operations; the ability of Arcadium Lithium to retain and hire key personnel; potential adverse reactions or changes to business or governmental relationships resulting from the announcement or completion of the Transaction; certain restrictions during the pendency of the Transaction that may impact Arcadium Lithium's ability to pursue certain business opportunities or strategic transactions; significant transaction costs associated with the Transaction; the possibility that the Transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; the occurrence of any event, change or other circumstance that could give rise to the termination of the Transaction, including in circumstances requiring Arcadium Lithium to pay a termination fee or other expenses; competitive responses to the Transaction; the supply and demand in the market for our products as well as pricing for lithium and high-performance lithium compounds; our ability to realize the anticipated benefits of the integration of the businesses of Livent and Allkem or of any future acquisitions; our ability to acquire or develop additional reserves that are economically viable; the existence, availability and profitability of mineral resources and mineral and ore reserves; the success of our production expansion efforts, research and development efforts and the development of our facilities; our ability to retain existing customers; the competition that we face in our business; the development and adoption of new battery technologies; additional funding or capital that may be required for our operations and expansion plans; political, financial and operational risks that our lithium extraction and production operations, particularly in Argentina, expose us to; physical and other risks that our operations and suppliers are subject to; our ability to satisfy customer qualification processes or customer or government quality standards; global economic conditions, including inflation, fluctuations in the price of energy and certain raw materials; the ability of our joint ventures, affiliated entities and contract manufacturers to operate according to their business plans and to fulfill their obligations; severe weather events and the effects of climate change; extensive and dynamic environmental and other laws and regulations; our ability to obtain and comply with required licenses, permits and other approvals; and other factors described under the caption entitled "Risk Factors" in Arcadium Lithium's 2024 Form 10-K filed with the SEC on February 27, 2025, as well as Arcadium Lithium's other SEC filings and public communications. Although Arcadium Lithium believes the expectations reflected in the forward-looking statements are reasonable, Arcadium Lithium cannot guarantee future results, level of activity, performance or achievements. Moreover, neither Arcadium Lithium nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Arcadium Lithium is under no duty to update any of these forward-looking statements after the date of this news release to conform its prior statements to actual results or revised expectations. ARCADIUM LITHIUM PLC CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in millions, except per share data) Three Months Ended Twelve Months Ended December 31, December 31, 2024 2023 (1) 2024 2023 (1) Revenue $ 289.0 $ 181.8 $ 1,007.8 $ 882.5 Cost of sales 243.4 85.7 719.2 344.1 Gross margin 45.6 96.1 288.6 538.4 Impairment charges — — 51.7 — Selling, general and administrative expenses 31.7 16.1 126.8 63.2 Research and development expenses 2.6 2.5 6.4 5.8 Restructuring and other charges 45.8 21.9 157.2 56.9 Total costs and expenses 323.5 126.2 1,061.3 470.0 (Loss)/income from operations before equity in net loss of unconsolidated affiliates, interest income, net, loss on debt extinguishment and other (gains)/losses (34.5) 55.6 (53.5) 412.5 Equity in net loss of unconsolidated affiliates 1.6 1.1 7.5 23.1 Interest income, net (1.5) — (20.3) — Loss on debt extinguishment — — 1.1 — Other (gains)/losses (50.4) 5.7 (252.4) 0.4 Income from operations before income taxes 15.8 48.8 210.6 389.0 Income tax expense 23.2 11.1 78.9 58.9 Net (loss)/income $ (7.4) $ 37.7 $ 131.7 $ 330.1 Net income attributable to noncontrolling interests 6.8 — 28.5 — Net (loss)/income attributable to Arcadium Lithium plc $ (14.2) $ 37.7 $ 103.2 $ 330.1 Basic (loss)/earnings per ordinary share $ (0.01) $ 0.09 $ 0.10 $ 0.76 Diluted (loss)/earnings per ordinary share $ (0.01) $ 0.07 $ 0.09 $ 0.66 Weighted average ordinary shares outstanding - basic 1,075.5 432.6 1,069.8 432.4 Weighted average ordinary shares outstanding - diluted 1,075.5 503.0 1,138.7 503.4 _______________________ 1. For the three and twelve months ended December 31, 2023, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent's operations for three and twelve months ended December 31, 2023 which do not include the operations of Allkem. ARCADIUM LITHIUM PLC RECONCILIATION OF NON-GAAP FINANCIAL MEASURES RECONCILIATION OF NET (LOSS)/ INCOME ATTRIBUTABLE TO ARCADIUM LITHIUM PLC TO ADJUSTED EBITDA (NON-GAAP) (Unaudited) Three Months Ended Twelve Months Ended December 31, December 31, (In Millions) 2024 2023 (1) 2024 2023 (1) Net (loss)/income attributable to Arcadium Lithium plc $ (14.2) $ 37.7 $ 103.2 $ 330.1 Add back: Net income attributable to noncontrolling interests 6.8 — 28.5 — Interest income, net (1.5) — (20.3) — Income tax expense 23.2 11.1 78.9 58.9 Depreciation and amortization 45.9 8.1 113.7 29.6 EBITDA (Non-GAAP) (2) 60.2 56.9 304.0 418.6 Add back: Argentina remeasurement (gains)/losses (a) (44.7) 53.4 (171.0) 73.9 Impairment charges (b) — — 51.7 — Restructuring and other charges (c) 45.8 21.9 157.2 56.9 Loss on debt extinguishment (d) — — 1.1 — Inventory step-up, Allkem Livent Merger (e) 11.0 — 32.0 — Other losses/(gains) (f) 1.4 0.9 (5.0) 16.7 Subtract: Blue Chip Swap gain (g) — (42.2) (45.2) (63.6) Argentina interest income (h) — — (0.3) — Adjusted EBITDA (Non-GAAP) (2) $ 73.7 $ 90.9 $ 324.5 $ 502.5 ___________________ 1. Represents the results of predecessor Livent's operations for three and twelve months ended December 31, 2023 which do not include the operations of Allkem. 2. We evaluate operating performance using certain Non-GAAP measures such as EBITDA, which we define as net income attributable to Arcadium Lithium plc plus noncontrolling interests, interest expense, net, income tax expense and depreciation and amortization; and Adjusted EBITDA, which we define as EBITDA adjusted for Argentina remeasurement (gains)/losses, impairment charges, restructuring and other charges, Allkem Livent Merger inventory step-up, certain Blue Chip Swap gains and other losses/(gains). Management believes the use of these Non-GAAP measures allows management and investors to compare more easily the financial performance of its underlying business from period to period. The Non-GAAP information provided may not be comparable to similar measures disclosed by other companies because of differing methods used by other companies in calculating EBITDA and Adjusted EBITDA. These measures should not be considered as a substitute for net income or other measures of performance or liquidity reported in accordance with U.S. GAAP. The above table reconciles EBITDA and Adjusted EBITDA from net income attributable to Arcadium Lithium plc. a. Represents impact of currency fluctuations primarily on deferred income tax assets and liabilities. Also includes impact of currency fluctuations on other tax assets and liabilities and on long-term monetary assets associated with our capital expansion as well as foreign currency devaluations. The remeasurement (gains)/losses are included within Other (gains)/losses in our consolidated statements of operations but are excluded from our calculation of Adjusted EBITDA because of: i.) their nature as income tax related; ii.) their association with long-term capital projects which will not be operational until future periods; or iii.) the severity of the devaluations and their immediate impact on our operations in the country. b. In the third quarter of 2024, the Company's plan to place its Mt Cattlin spodumene operation in Western Australia into care and maintenance resulted in a non-cash charge of $51.7 million for the twelve months ended December 31, 2024, and was recorded to Impairment charges in the consolidated statement of operations. The impairment charges are excluded from our calculation of Adjusted EBITDA because the charges are nonrecurring. c. We continually perform strategic reviews and assess the return on our business. This sometimes results in management changes or in a plan to restructure the operations of our business. As part of these restructuring plans, demolition costs and write-downs of long-lived assets may occur. The three months ended December 31, 2024 and 2023 include costs related to the Allkem Livent Merger of $4.9 million and $21.8 million, respectively. The years ended December 31, 2024 and 2023 include costs related to the Allkem Livent Merger of $103.9 million and $54.1 million, respectively. 2024 also includes costs related to the Rio Tinto Transaction of $23.2 million. The years ended December 31, 2024 and 2023 include severance-related costs of $19.0 million and $2.4 million, respectively. d. The twelve months ended December 31, 2024 includes a $0.9 million prepayment fee incurred when the Sal de Vida Project Financing Facility was repaid in its entirety by SDJ on May 30, 2024 and $0.2 million for the partial write-off of deferred financing costs for amendments to the Revolving Credit Facility. The debt extinguishment losses are excluded from our calculation of Adjusted EBITDA because the loss is nonrecurring. e. Relates to the step-up in inventory recorded for Allkem Livent Merger for the twelve months ended December 31, 2024 as a result of purchase accounting, excluded from Adjusted EBITDA as the step-up is considered a one-time, non-recurring cost. f. The three and twelve months ended December 31, 2024 primarily represents foreign currency remeasurement gains related to U.S. dollar-denominated cash balances temporarily held at a foreign currency-functional subsidiary. The three and twelve months ended December 31, 2023, prior to consolidation of Nemaska Lithium Inc. ("NLI") on October 18, 2023, represents our 50% ownership interest in costs incurred for certain project-related costs to align NLI's reported results with Arcadium's capitalization policies and interest expense incurred by NLI, all included in Equity in net loss of unconsolidated affiliates in our consolidated statements of operations. The Company consolidates NLI on a one-quarter lag basis and prior to October 18, 2023, accounted for its equity method investment in NLI on a one-quarter lag basis. g. Represents non-recurring gain from the sale in Argentina pesos of Argentina Sovereign U.S. dollar-denominated bonds due to the divergence of Argentina's Blue Chip Swap market exchange rate from the official rate. h. Represents interest income received from the Argentina government for the period beginning when the recoverability of certain of our expansion-related VAT receivables were approved by the Argentina government and ending on the date when the reimbursements were paid by the Argentina government but is excluded from our calculation of Adjusted EBITDA because of its association with long-term capital projects which will not be operational until future periods. RECONCILIATION OF NET (LOSS)/INCOME ATTRIBUTABLE TO ARCADIUM LITHIUM PLC (GAAP) TO ADJUSTED AFTER-TAX EARNINGS (NON-GAAP) (Unaudited) Three Months Ended Twelve Months Ended December 31, December 31, (In Millions, except per share amounts) 2024 2023 (1) 2024 2023 (1) Net (loss)/income attributable to Arcadium Lithium plc $ (14.2) $ 37.7 $ 103.2 $ 330.1 Add back: Net income attributable to noncontrolling interests 6.8 — 28.5 — Special charges: Argentina remeasurement (gains)/losses (a) (44.7) 53.4 (171.0) 73.9 Impairment charges (b) — — 51.7 — Restructuring and other charges (c) 45.8 21.9 157.2 56.9 Loss on debt extinguishment (d) — — 1.1 — Inventory step-up, Allkem Livent Merger (e) 11.0 — 32.0 — Other losses/(gains) (f) 1.4 0.9 (5.0) 16.7 Blue Chip Swap gain (g) — (42.2) (45.2) (63.6) Argentina interest income (h) — — (0.3) — Non-GAAP tax adjustments (i) 6.4 (0.9) 10.0 (18.0) Adjusted after-tax earnings (Non-GAAP) (2) $ 12.5 $ 70.8 $ 162.2 $ 396.0 Diluted (loss)/earnings per ordinary share (GAAP) $ (0.01) $ 0.07 $ 0.09 $ 0.66 Net income attributable to noncontrolling interests, per diluted share 0.01 — 0.03 — Special charges per diluted share, before tax: Argentina remeasurement (gains)/losses, per diluted share (0.04) 0.11 (0.16) 0.15 Impairment charges, per diluted share — — 0.04 — Restructuring and other charges, per diluted share 0.04 0.04 0.14 0.11 Inventory step-up, Allkem Livent Merger, per diluted share 0.01 — 0.03 — Other losses, per diluted share — — — 0.03 Blue Chip Swap gain, per diluted share — (0.08) (0.04) (0.12) Non-GAAP tax adjustments per diluted share — — 0.01 (0.04) Diluted adjusted after-tax earnings per share (Non-GAAP) (2) $ 0.01 $ 0.14 $ 0.14 $ 0.79 Weighted average number of shares outstanding used in diluted adjusted after-tax earnings per share computations (Non-GAAP) 1,145.6 503.0 1,138.7 503.4 ____________________ 1. For the three and twelve months ended December 31, 2023, diluted earnings per ordinary share (GAAP), weighted average ordinary shares outstanding - diluted (Non-GAAP) and all per diluted share amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent's operations for three and twelve months ended December 31, 2023 which do not include the operations of Allkem. 2. The Company believes that the Non-GAAP financial measures "Adjusted after-tax earnings" and "Diluted adjusted after-tax earnings per share" provide useful information about the Company's operating results to management, investors and securities analysts. Adjusted after-tax earnings excludes the effects of nonrecurring charges/(income) and tax-related adjustments. The Company also believes that excluding the effects of these items from operating results allows management and investors to compare more easily the financial performance of its underlying business from period to period. Diluted adjusted after-tax earnings per share (Non-GAAP) is calculated using weighted average common shares outstanding - diluted. a. Represents impact of currency fluctuations primarily on deferred income tax assets and liabilities. Also includes impact of currency fluctuations on other tax assets and liabilities and on long-term monetary assets associated with our capital expansion as well as foreign currency devaluations. The remeasurement (gains)/losses are included within Other (gains)/losses in our consolidated statements of operations but are excluded from our calculation of Adjusted EBITDA because of: i.) their nature as income tax related; ii.) their association with long-term capital projects which will not be operational until future periods; or iii.) the severity of the devaluations and their immediate impact on our operations in the country. b. In the third quarter of 2024, the Company's plan to place its Mt Cattlin spodumene operation in Western Australia into care and maintenance resulted in a non-cash charge of $51.7 million for the twelve months ended December 31, 2024, and was recorded to Impairment charges in the consolidated statement of operations. The impairment charges are excluded from our calculation of Adjusted EBITDA because the charges are nonrecurring. c. We continually perform strategic reviews and assess the return on our business. This sometimes results in management changes or in a plan to restructure the operations of our business. As part of these restructuring plans, demolition costs and write-downs of long-lived assets may occur. The three months ended December 31, 2024 and 2023 include costs related to the Allkem Livent Merger of $4.9 million and $21.8 million, respectively. The years ended December 31, 2024 and 2023 include costs related to the Allkem Livent Merger of $103.9 million and $54.1 million, respectively. 2024 also includes costs related to the Rio Tinto Transaction of $23.2 million. The years ended December 31, 2024 and 2023 include severance-related costs of $19.0 million and $2.4 million, respectively. d. The twelve months ended December 31, 2024 includes a $0.9 million prepayment fee incurred when the Sal de Vida Project Financing Facility was repaid in its entirety by SDJ on May 30, 2024 and $0.2 million for the partial write-off of deferred financing costs for amendments to the Revolving Credit Facility. The debt extinguishment losses are excluded from our calculation of Adjusted EBITDA because the loss is nonrecurring. e. Relates to the step-up in inventory recorded for Allkem Livent Merger for the twelve months ended December 31, 2024 as a result of purchase accounting, excluded from Adjusted EBITDA as the step-up is considered a one-time, non-recurring cost. f. The three and twelve months ended December 31, 2024 primarily represents foreign currency remeasurement gains related to U.S. dollar-denominated cash balances temporarily held at a foreign currency-functional subsidiary. The three and twelve months ended December 31, 2023, prior to consolidation of Nemaska Lithium Inc. ("NLI") on October 18, 2023, represents our 50% ownership interest in costs incurred for certain project-related costs to align NLI's reported results with Arcadium's capitalization policies and interest expense incurred by NLI, all included in Equity in net loss of unconsolidated affiliates in our consolidated statements of operations. The Company consolidates NLI on a one-quarter lag basis and prior to October 18, 2023, accounted for its equity method investment in NLI on a one-quarter lag basis. g. Represents non-recurring gain from the sale in Argentina pesos of Argentina Sovereign U.S. dollar-denominated bonds due to the divergence of Argentina's Blue Chip Swap market exchange rate from the official rate. h. Represents interest income received from the Argentina government for the period beginning when the recoverability of certain of our expansion-related VAT receivables were approved by the Argentina government and ending on the date when the reimbursements were paid by the Argentina government but is excluded from our calculation of Adjusted EBITDA because of its association with long-term capital projects which will not be operational until future periods. i. The Company excludes the GAAP tax provision, including discrete items, from the Non-GAAP measure Diluted adjusted after-tax earnings per share, and instead includes a Non-GAAP tax provision based upon the annual Non-GAAP effective tax rate. The GAAP tax provision includes certain discrete tax items including, but not limited to: income tax expenses or benefits that are not related to operating results in the current year; tax adjustments associated with fluctuations in foreign currency remeasurement of certain foreign operations; certain changes in estimates of tax matters related to prior fiscal years; certain changes in the realizability of deferred tax assets and related accounting impacts; and changes in tax law. Management believes excluding these discrete tax items assists investors and securities analysts in understanding the tax provision and the effective tax rate related to operating results thereby providing investors with useful supplemental information about the Company's operational performance. The income tax expense/(benefit) on special charges/(income) is determined using the applicable rates in the taxing jurisdictions in which the special charge or income occurred and includes both current and deferred income tax expense/(benefit) based on the nature of the Non-GAAP performance measure. Three Months Ended Twelve Months Ended December 31, December 31, (in Millions) 2024 2023 2024 2023 Non-GAAP tax adjustments: Income tax benefit on restructuring and other charges and other corporate costs $ (8.0) $ (3.4) $ (34.9) $ (7.0) Revisions to our tax liabilities due to finalization of prior year tax returns 2.4 — (1.7) (0.4) Foreign currency remeasurement (net of valuation allowance) and other discrete items 7.1 (1.1) 45.5 (16.2) Blue Chip Swap gain (0.2) 4.5 10.3 6.7 Tax effect of impairment charges — — (15.5) — Other discrete items 5.1 (0.9) 6.3 (1.1) Total Non-GAAP tax adjustments $ 6.4 $ (0.9) $ 10.0 $ (18.0) RECONCILIATION OF CASH (USED IN)/PROVIDED BY OPERATING ACTIVITIES (GAAP) TO ADJUSTEDCASH PROVIDED BY OPERATIONS (NON-GAAP) (Unaudited) Twelve Months Ended December 31, (In Millions) 2024 2023 (1) Cash (used in)/provided by operating activities (GAAP) $ (176.0) $ 297.3 Restructuring and other charges 192.1 28.7 Argentina interest income (1.5) — Adjusted cash provided by operations (Non-GAAP) (2) $ 14.6 $ 326.0 ___________________ 1. Represents the results of predecessor Livent's operations for twelve months ended December 31, 2023 which do not include the operations of Allkem. 2. The Company believes that the Non-GAAP financial measure Adjusted cash provided by operations provides useful information about the Company's cash flows to investors and securities analysts. Adjusted cash provided by operations excludes the effects of transaction-related cash flows. The Company also believes that excluding the effects of these items from cash (used in)/provided by operating activities allows management and investors to compare more easily the cash flows from period to period. RECONCILIATION OF LONG-TERM DEBT (GAAP) AND CASH AND CASH EQUIVALENTS (GAAP) TO NET DEBT (NON-GAAP) (Unaudited) (In Millions) December 31, 2024 December 31, 2023 (1) Long-term debt (including current maturities) (GAAP) (a) $ 960.6 $ 302.0 Less: Cash and cash equivalents (GAAP) (93.2) (237.6) Net debt (Non-GAAP) (2) $ 867.4 $ 64.4 ___________________ 1. Represents the financial position of predecessor Livent as of December 31, 2023, which does not include the financial position of Allkem. 2. The Company believes that the non-GAAP financial measure "Net debt" provides useful information about the Company's cash flows and liquidity to investors and securities analysts. a. Presented net of unamortized transaction costs and discounts of $73.8 million and $22.2 million as of December 31, 2024 and 2023, respectively. RECONCILIATION OF CASH AND CASH EQUIVALENTS (GAAP) TO ADJUSTED CASH AND DEPOSITS (NON-GAAP) The following table provides a reconciliation of Arcadium Lithium's Cash and cash equivalents (GAAP) to Adjusted cash and deposits (Non-GAAP), on an unaudited basis for illustrative purposes. We define Adjusted cash and deposits (Non-GAAP) as Cash and cash equivalents, plus restricted cash in Other non-current assets, less Nemaska Lithium Cash and cash equivalents consolidated by Arcadium on a one-quarter lag, plus Nemaska Lithium Cash and cash equivalents not on a one-quarter lag. Our management believes that this measure provides useful information about the Company's balances and liquidity to investors and securities analysts. Such measure may not be comparable to similar measures disclosed by other companies because of differing methods used by other companies in calculating Adjusted cash and deposits. These measures should not be considered as a substitute for Cash and cash equivalents or other measures of liquidity reported in accordance with U.S. GAAP. December 31, 2024 2023 (1) (in Millions) Arcadium Lithium Cash and cash equivalents (GAAP) $ 93.2 $ 237.6 Allkem Cash and cash equivalents — 681.4 Add: Restricted cash in Other non-current assets: Project Loan Facility guarantee - Stage 2 of Olaroz Plant (SDJ) 18.1 24.6 Project Financing Facility guarantee - Sal de Vida (SDV) (2) — 32.5 Other 5.3 5.0 Less: Nemaska Lithium Cash and cash equivalents as of Sept. 30, 2024 and October 18, 2023, respectively, consolidated by Arcadium on a one-quarter lag (11.4) (133.5) Arcadium Lithium, excluding Nemaska Lithium 105.2 847.6 Nemaska Lithium Cash and cash equivalents not on a one-quarter lag (3) 28.2 44.2 Adjusted cash and deposits (Non-GAAP) (4) 133.4 891.8 _________________ 1. This unaudited information of the combined company as of December 31, 2023 is for illustrative purposes and was derived from the historical consolidated financial information of Livent, Allkem and Nemaska Lithium. 2. On May 30, 2024, SDV paid the outstanding principal balance of $47.0 million, a prepayment fee of $0.9 million and accrued interest and commitment fees of $1.3 million to repay the Project Financing Facility in its entirety. 3. The presentation reflects NLI's actual balance at that date, not on a one-quarter lag. This differs from Nemaska Lithium cash and cash equivalents included in Arcadium Lithium's consolidated balance sheet as of December 31, 2024 of $11.4 million, representing NLI's balance as of September 30, 2024 as we consolidate NLI on a one-quarter lag. In the fourth quarter of 2024, the Company contributed cash of $96.7 million to Nemaska Lithium which, due to one-quarter lag reporting, is not yet recorded in our consolidation of Nemaska. The balance is recorded to Other assets - noncurrent because the cash is expected to be used by Nemaska primarily for capital expenditures. IQ contemporaneously made an equal contribution in the fourth quarter of 2024 which, due to one-quarter lag reporting, is not recorded in our consolidation of Nemaska. On March 28, 2024 and January 3, 2025, Nemaska Lithium received cash of $150 million and $125 million related to the second and third advance payments, respectively, in connection with a customer supply agreement repayable in equal quarterly installments beginning in January 2027 and ending in October 2031. 4. $124.7 million and $176.9 million is required to be reserved or restricted at December 31, 2024 and December 31, 2023, respectively, to provide collateral or cash backing for guarantees primarily on Allkem debt facilities, including $23.4 million and $62.1 million at December 31, 2024 and December 31, 2023, respectively, in Other non-current assets in our consolidated balance sheet. ARCADIUM LITHIUM PLC CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In Millions) December 31, 2024 December 31, 2023 (1) Cash and cash equivalents $ 93.2 $ 237.6 Trade receivables, net of allowance of less than $0.1 in 2024 and $0.3 in 2023 130.3 106.7 Inventories, net 417.6 217.5 Prepaid and other current assets 218.7 86.4 Total current assets 859.8 648.2 Investments 36.9 34.8 Property, plant and equipment, net of accumulated depreciation of $351.2 in 2024 and $269.1 in 2023 7,371.2 2,237.1 Goodwill 1,362.9 120.7 Other intangibles, net 62.2 53.4 Deferred income taxes 37.8 1.4 Right of use assets - operating leases, net 47.0 6.8 Other assets 412.3 127.7 Total assets $ 10,190.1 $ 3,230.1 Total current liabilities 789.0 268.6 Long-term debt 671.7 299.6 Contract liability - long-term 238.1 217.8 Other long-term liabilities 1,310.5 160.3 Equity 7,180.8 2,283.8 Total liabilities and equity $ 10,190.1 $ 3,230.1 _________________ 1. Represents the financial position of predecessor Livent as of December 31, 2023, which does not include the financial position of Allkem. ARCADIUM LITHIUM PLC CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Twelve Months Ended December 31, (In Millions) 2024 2023 (1) Cash (used in)/provided by operating activities $ (176.0) $ 297.3 Cash used in investing activities (445.3) (228.3) Cash provided by/(used in) financing activities 492.4 (20.4) Effect of exchange rate changes on cash (15.5) — (Decrease)/increase in cash and cash equivalents (144.4) 48.6 Cash and cash equivalents, beginning of period 237.6 189.0 Cash and cash equivalents, end of period $ 93.2 $ 237.6 ___________________ 1. Represents the results of predecessor Livent's operations for the twelve months ended December 31, 2023 which do not include the operations of Allkem. ARCADIUM LITHIUM PLC LONG-TERM DEBT (Unaudited) Interest Rate Percentage Maturity Date December 31,2024 December 31,2023 (in Millions) SOFRborrowings Base rateborrowings Revolving Credit Facility (1) 6.18 % 8.25 % 2027 $ 344.0 $ — 4.125% Convertible Senior Notes due 2025 4.125 % 2025 245.8 245.8 Transaction costs - 2025 Notes (0.9) (2.4) Nemaska - Prepayment agreement (2) 8.9 % 75.0 75.0 Discount - Prepayment agreement (20.1) (19.8) Nemaska - Prepayment agreement - tranche 2 (2) 9.4 % 150.0 — Discount - Prepayment agreement (52.8) — Nemaska - Other 0.6 3.4 Debt assumed in Allkem Livent Merger (3) Project Loan Facility - Stage 2 of Olaroz Plant 2.61 % 2029 135.0 — Affiliate Loans with TTC 14.30 % 2030 81.5 — Affiliate Loan with TLP 10.03 % 2026 2.5 — Total debt assumed in Allkem Livent Merger 219.0 — Subtotal long-term debt (including current maturities) 960.6 302.0 Less current maturities (288.9) (2.4) Total long-term debt $ 671.7 $ 299.6 ________________________ 1. Represents the financial position of predecessor Livent as of December 31, 2023, which does not include the financial position of Allkem. 2. Represents advance payments in connection with customer supply agreement which do not have a contractual interest rate or bear any actual interest and are repayable in equal quarterly installments beginning in January 2027 and ending in October 2031. Represents U.S. GAAP imputed interest rate. 3. On September 10, 2024, SDJ paid the outstanding principal balance of $9.1 million to repay Stage 1 of the Olaroz Plan Project Loan Facility in its entirety. On May 30, 2024, SDV paid the outstanding principal balance of $47.0 million, a prepayment fee of $0.9 million and accrued interest and commitment fees of $1.3 million to repay the Project Financing Facility in its entirety. Logo - https://mma.prnasia.com/media2/2310012/Arcadium_Lithium_Horizontal_Logo.jpg?p=medium600
Metabolon's expertise extends beyond metabolomics to include data insights and software solutions for multiomics research MORRISVILLE, N.C., Feb. 27, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, announces new multiomics biomarker discovery capabilities within Metabolon's recently launched Integrated Bioinformatics Platform. This new functionality includes multiomics predictive modeling, latent factor analysis, multiomics pathway analysis using public tools like Reactome, and sophisticated multiomic data visualization resources. The global multiomics market was valued at $2.4 billion in 2023 and is projected to reach $6.4 billion by 2030. Since 2012, scientific publications featuring multiomic data have increased 63% annually. Despite the growing importance of multiomics research, successfully combining genomic, transcriptomic, proteomic, and metabolomic data can be time-consuming and expensive. Metabolon's new multiomics biomarker discovery functionality provides powerful and easily accessible online bioinformatics tools that enable multiomics research and provide the most complete out-of-the-box representation of the phenotype available. "Metabolon's new multiomic biomarker discovery capabilities make integrating disparate omics data sets easier and help our customers build powerful studies that incorporate metabolite and lipid data seamlessly with other omics information," said Dr. Karl Bradshaw, Chief Business Officer at Metabolon. "Reactome's comprehensive and expertly curated pathway data provides a critical foundation for multiomic analysis," said Dr. Lincoln Stein, Lead Principal Investigator at Reactome. "We're thrilled to see Metabolon harnessing our resource to enable researchers to unravel the complexities of biological systems." Metabolon's new bioinformatics functionality is available via a comprehensive suite of web-based tools: Multiomics Predictive Modeling Upload and integrate diverse omics data using algorithms like logistic regression and random forest to build multiomics models. Explore model performance and evaluate multiomic feature contributions to identify potential biomarkers for further analysis. Latent Factor Analysis of Multiomics Data Identify latent factors representing underlying biological variation. Explore relationships that span multiomic layers to uncover biologically relevant biomarkers and guide further research. Multiomics Pathway Enrichment Analysis Using Reactome (https://reactome.org/) Map metabolites to other omics entities (e.g., genes and proteins) using the most comprehensive and curated reference of biological pathways. Statistically rank pathways from the Reactome database that are driving variation/signal found in your specific dataset. Leverage Metabolon's integrated bioinformatics platform to gain improved insights into your most critical research questions – explore the interplay of your biomarkers and their effects on wider-reaching biological mechanisms. To learn more, please visit: Metabolon's Integrated Bioinformatics Platform: https://www.metabolon.com/bioinformatics About Metabolon Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other 'omics' technologies. With more than 20 years, 10,000+ projects, 3,400+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon's Global Discovery Panel is powered by the world's largest proprietary metabolomics reference library. Metabolon's industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter. About ReactomeReactome is an open-source, open-access, manually curated, and peer-reviewed pathway database. Our goal is to provide intuitive bioinformatics tools for the visualization, interpretation, and analysis of pathway knowledge to support basic and clinical research, genome analysis, modeling, systems biology, and education. Founded in 2003, the Reactome project is led by Lincoln Stein of OICR, Peter D'Eustachio of NYU Langone Health, Henning Hermjakob of EMBL-EBI, and Guanming Wu of OHSU. The Reactome database and website enable scientists, researchers, students, and educators to find, organize, and utilize biological information to support data visualization, integration, and analysis. About MetabolomicsMetabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic and external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug's mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.
- Integrated Smart Elderly Care, Green Infrastructure, and Eco-Agriculture Offer Globally Replicable Rural Model SHANGHAI, Feb. 27, 2025 /PRNewswire/ -- The China Association of Public Companies recently recognized SANY Heavy Industry and the SANY Foundation's rural revitalization project in Daotong Village, Lianyuan City, Hunan Province as a 2024 Best Practice Case for Rural Revitalization by Listed Companies. Launched in 2019, this flagship initiative supports China's rural revitalization and the UN's Sustainable Development Goals (SDGs). The project integrates smart elderly care, green infrastructure, and eco-agriculture, establishing a sustainable and replicable model for global rural development. Smart Elderly Care: Building a Sustainable Aging-Friendly SystemIn Daotong Village, where the elderly constitute 21% of the population, an initiative has established a comprehensive care system that blends the expertise of social workers, professional caregivers, and cutting-edge smart healthcare technology. The central healthcare facility, now a hub for health management, daytime care, and cultural engagement, accommodates 12,500 visits each year. The facility has created 631 digital health profiles to provide personalized care for each resident. Additionally, in collaboration with both public and private sectors, the project has facilitated aging-friendly renovations in 17 low-income homes, ensuring their occupants' safety with advanced emergency response technologies. To ensure the initiative's sustainability and potential replication elsewhere, a team has compiled a standardized operational manual. Green Infrastructure: Driving Sustainable Rural ProgressThe project upgraded Daotong's infrastructure, including overhauling its drinking water network and restoring Longtang Lake's ecosystem to meet WHO water standards. A 530-unit solar-powered streetlight network cuts annual carbon emissions by 42 tons while illuminating all main roads. The innovative Daotong Micro-Fund empowers community governance, funding eight public space upgrades and fostering a "co-creation, co-management, and co-sharing" model. The project revitalized 158 acres of abandoned farmland through chemical-free farming, creating 64 jobs and lifting over 40 impoverished households to stable income levels. The introduction of high-value products like multicolor brown rice and "light-snow" strawberries to broader markets has significantly enhanced their agricultural value. Culture & Education: Unleashing Rural Soft PowerThe Daotong Academy and volunteer network form a cultural revitalization matrix. The academy has hosted 110 training sessions on smart farming tools and nature-based education, benefiting 1,057 villagers. A dedicated 97-member volunteer team contributes over 3,000 service hours annually. Cultural initiatives, such as the Farmers' Harvest Festival, have drawn 1,100 participants, strengthening community cohesion and building a unique rural cultural identity. Guided by the ethos of "providing scientific knowledge for public benefits", SANY Heavy Industry and the SANY Foundation prioritize data-driven monitoring and professional operations to ensure long-term sustainability. The project has been honored as a National Model Aging-Friendly Community, a Key Rural Revitalization Initiative in Hunan Province, and a Golden Key - China Action for SDGs awardee. Moving forward, SANY Group will deepen its integrated rural development efforts, refining a globally replicable model that promotes sustainable development and contributes Chinese wisdom and the SANY Solution to rural transformation worldwide.
NEXTCHEM's proprietary NX AdWinMethanol® Zero offers an innovative process combining cutting-edge solutions to minimize carbon emissions, thanks to its autothermal reforming (ATR) technology The plant is poised to be one of the largest standalone ultra-low carbon chemical production facility in the world, with a total output in excess of 2.1 million ton/year The whole package for the project is estimated to be around €250 million and includes also the basic engineering, proprietary and critical equipment supply, as well as assistance to commissioning, start-up and operation of the facility MILAN, Feb. 27, 2025 /PRNewswire/ -- MAIRE (MAIRE.MI) announces that NEXTCHEM's subsidiary KT Tech has been awarded a licensing contract for the implementation of NEXTCHEM's proprietary NX AdWinMethanol® Zero technology for Pacifico Mexinol, an ultra-low carbon methanol facility near Los Mochis, Sinaloa, on the Pacific coast of Mexico, with an output in excess of 2.1 million tons per year. Transition Industries LLC, a company based in Houston, Texas, is a developer of world-scale, ultra-low carbon emissions methanol and hydrogen facilities in North America. Transition Industries is jointly developing Pacifico Mexinol with the International Finance Corporation (IFC), a member of the World Bank Group. When it initiates operation in 2028, Pacifico Mexinol is expected to be the largest single ultra-low carbon methanol facility in the world – producing approximately 350,000 metric tons of green methanol and 1.8 million metric tons of blue methanol annually from natural gas with carbon capture. The value of the licensing award, which will be partly recognized upfront and partly at Final Investment Decision, is in the low tens of million euro, in line with transactions of this kind. The whole package is estimated to be about €250 million, also including the basic engineering, proprietary and critical equipment supply, as well as assistance to commissioning, start-up and operation of the facility. The NX AdWinMethanol® Zero technology developed by GasConTec, NEXTCHEM's subsidiary dedicated to low-carbon hydrogen and methanol solutions, integrates its proprietary Autothermal Reforming (ATR) process and methanol synthesis loop and proprietary CO2 capture technologies. This technology further minimizes carbon emissions to nearly zero by converting captured CO2 and green hydrogen into ultra-low-carbon methanol. This innovative technological approach increases the sustainability of the methanol production process, reflecting Pacifico Mexinol's commitment to addressing climate change. Ultra-low carbon methanol can be used to facilitate the decarbonization of the hard to abate chemicals sectors. The methanol produced by Pacifico Mexinol will facilitate the decarbonization of hundreds of downstream everyday products, including plastics, paints, car parts and construction materials. Alessandro Bernini, Chief Executive Officer of MAIRE, commented: "We are honored to support this strategic project with NEXTCHEM's cutting-edge technologies for ultra-low carbon energy vectors. This important achievement confirms our pivotal role in the energy transition and our ability to deliver advanced market-ready solutions that enable our clients to lead the way in producing clean chemical products." Rommel Gallo, Chief Executive Officer of Transition Industries, commented: "We are pleased to enter into this strategic relationship with NEXTCHEM and implement a world-class technology for the largest ultra-low carbon methanol facility in the world. We look forward to working together with NEXTCHEM to accelerate and lead the decarbonization of the global methanol and chemicals sectors."
SHANGHAI, Feb. 24, 2025 /PRNewswire/ -- The productronica China serves as a crucial platform for showcasing and exchanging ideas within the electronic intelligent manufacturing sector. It will be open grandly from March 26 to 28, 2025, at the Shanghai New International Expo Centre (Halls E1-E5, W1-W4). productronica China 2025 will cover nearly 100,000 square meters and is expected to draw over 1,000 premium companies from the electronic manufacturing field. These companies will showcase a full range of products and technologies from the electronic manufacturing supply chain, including electronic chemical materials, dispensing and bonding solutions, automated electronic assembly, testing and measurement tools, quality assurance services, electronic manufacturing services, surface mount technology (SMT), cable processing, component manufacturing, motion control and drive technology, sensor technology, robotics, AGVs, intelligent warehousing, etc. The exhibition is dedicated to orchestrating a grand event that combines innovative technology, cutting-edge products, and business networking for the Asian electronic manufacturing sector. It emphasizes the latest industry dynamics and future growth trends, offering an unparalleled viewing experience for professionals from automotive, renewable energy, communication electronics, consumer electronics, industrial electronics, and rail transit sectors. Additionally, it facilitates precise demand alignment for upstream and downstream enterprises within the industry, offering opportunities for shared technical insights and industry trend forecasting, fostering interconnected development for mutual growth. The visitor registration has been launched. Register now and learn more highlights of productronia China 2025: https://pc.global-eservice.com/?lang=en&channel=mts Offer multi-dimensional scenario-based exhibition experience and showcase innovative achievements of SMT technology and equipment productronica China launched the SMT Demo Line in 2014, successfully developing an innovative display format focused on solution demonstration and aimed at facilitating practical application. This helps visitors to more intuitively and vividly understand cutting-edge technologies and innovative solutions. In 2025, the exhibition will further expand the SMT section display, presenting more technological solutions to the Chinese electronic manufacturing industry through a scenario-based approach to inspire professional visitors with innovative ideas. Among these, the Smart Factory and the Micro-assembly Science & Technology Area will focus on promoting intelligent manufacturing development, guided by industrial intelligent upgrades. Focus on the surge of NEVs and foster new advancements in the cable processing industry As the technical advancements in NEVs progress, with enhanced vehicle performance and more comprehensive support services for batteries and motors, new opportunities arise for the technological upgrades in automotive cables, and the demand for cable processing and connector manufacturing continues to grow. The productronica China 2025 will strategically expand the display area for cable processing and connector manufacturing, showcasing various advanced cable processing equipment and connector products such as automated cable processing machines, crimping machines, and connector molds. These machines are capable of improving production efficiency and product quality, catering to the needs of various industries. Embrace the "carbon peaking and carbon neutrality" concept and explore new market opportunities in new energy and energy storage productronica China aligns with the development trends of the new energy and automotive industries, coordinating the promotion and application of technological innovation alongside infrastructure development. It is anchored in the new energy and automotive technology industry chain, expanding the market, and is dedicated to establishing a forward-thinking commercial platform for high-quality new energy and automotive technologies. This provides opportunities for exchange and learning within the automotive industry and supports the achievement of the "dual carbon" objectives. The new energy and automotive technology section at the productronica China 2025 will concentrate on new energy and automotive electronic applications. These include NEV testing technology, automotive PLC control systems, and innovative adhesive technologies for NEVs, offering a range of innovative solutions for the NEV sector. In addition, the productronica China 2025 will newly plan and introduce a super factory for energy storage automation. The intelligent factory digital system, along with smart logistics and warehousing systems integrated into the energy storage equipment, enhances production efficiency and reduces manufacturing costs. This advancement achieves an upgrade and transformation towards smart manufacturing, empowering downstream energy storage battery companies with formidable market competitiveness, and offering comprehensive intelligent solutions for the photovoltaic, lithium battery, and new energy industries and applications. During the event, targeted invitations will be extended to leading clients including CATL, BYD Motors, EVE, Sungrow, Envision Energy, HiTHIUM, Hyper Strong, among others. Introduce the Smart Factory & Micro-assembly Science & Technology Area and facilitate novel developments in industrial transformation The fully automatic SMT production line can automate the mounting process through highly precise machine operations and controls, enhancing production efficiency and product quality to meet the demands of various clients. The productronica China is dedicated to demonstrating the complete SMT soldering, DIP insertion, AOI inspection, testing, cleaning, and packaging processes through on-site live demonstrations of entire line equipment. productronica China is committed to driving industrial smart upgrades, proudly introducing the Micro-assembly Science & Technology Area focusing on applications such as micro LED/mini LED display chips, mobile phone miniature components, MEMS devices, RF devices, microwave devices, and hybrid circuits. Center on four key themes and hold multiple simultaneous forums to explore the industry's current trends During the exhibition, a series of professional events will also take place, including industry forums, technical competitions, and product award ceremonies. Dozens of forums will focus on four major themes: "Innovative productivity will promote the industry to realize high-quality development, and artificial intelligence will lead the industry into the future style", "Delve into the latest trends in new energy automotive electronics manufacturing within the framework of the 'double carbon' blueprint"; "Innovation empowers industry transformation, and technology steers the future", "Growing market demand and technology iteration bring new momentum to the growth of the advanced packaging industry". Expanding on and deriving from the four major themes, the forums will further delve into popular topics such as industrial robots, flexible manufacturing, energy storage and new energy, automotive cable processing, intelligent vehicle cockpits, intelligent manufacturing, advanced TGV materials and packaging, dispensing and adhesives, and new energy vehicle. Please click the link for more information: https://www.productronicachina.com.cn/en/supporting-program For further information, please contact Ms. Xing via email sinsia.xing@mm-sh.com Register now! productronicaChina2025
Exploring new opportunities within the fast-growing market of microfluidics BORDEAUX, France, Feb. 20, 2025 /PRNewswire/ -- Syensqo, a leading specialty chemicals company, is pleased to announce a strategic partnership with Emulseo, a French company specialized in formulations for microfluidic technology - the manipulation of liquids at microscopic scale. Under this agreement, Emulseo will include Syensqo's advanced solution, Galden® PFPE in its Fluo-Oil range of products to provide its customers with an essential component in creating reliable and performant droplet-based microfluidic analyses. Droplet-based microfluidics analysis is a widely used technique for the study and manipulation of liquids at a micro-scale using liquid micro-droplets. It has diverse applications, particularly in healthcare as it is one of the most precise and efficient ways to study DNA strands, cells, chemicals, or drugs using very small amounts of material. For example, it is used for the diagnosis of cancer diseases from blood samples, for the development of antibiotics and therapeutics treatments, and for conducting rapid COVID-19 testing through digital PCR. The partnership with Emulseo will leverage Syensqo's Galden® PFPE, a family of inert, high-performance, fluorinated fluids with outstanding properties enabling optimal performances of microfluidic systems thanks mainly to their chemical inertness, low viscosity and optical transparency. "We are thrilled to partner with Emulseo and bring our Galden® PFPE to the forefront of microfluidics technology," said Peter Browning, President of the Specialty Polymers Global business unit at Syensqo. "This collaboration underscores our commitment to innovation and expanding the applications of our materials to advance humanity, as our PFPE, usually used in the electronics industry, will now contribute to save lives through cancer detection and faster vaccine developments for example." "As a young innovative company, Emulseo is extremely proud to partner with a European industry leader such as Syensqo with a clear ambition to support innovation and to contribute to the development of cutting edge technologies in the health sector" added Emulseo CEO, Florine Maes. "Syensqo's high performance chemicals combined with our expertise and tailor-made quality controls for microfluidic requirements, will enhance our product offerings to meet our commitments to our scientific and industrial customers worldwide." Contact: sales@emulseo.com
A12 藝術空間
Chemical
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
